Unknown

Dataset Information

0

Integrative omics analyses broaden treatment targets in human cancer.


ABSTRACT: BACKGROUND:Although large-scale, next-generation sequencing (NGS) studies of cancers hold promise for enabling precision oncology, challenges remain in integrating NGS with clinically validated biomarkers. METHODS:To overcome such challenges, we utilized the Database of Evidence for Precision Oncology (DEPO) to link druggability to genomic, transcriptomic, and proteomic biomarkers. Using a pan-cancer cohort of 6570 tumors, we identified tumors with potentially druggable biomarkers consisting of drug-associated mutations, mRNA expression outliers, and protein/phosphoprotein expression outliers identified by DEPO. RESULTS:Within the pan-cancer cohort of 6570 tumors, we found that 3% are druggable based on FDA-approved drug-mutation interactions in specific cancer types. However, mRNA/phosphoprotein/protein expression outliers and drug repurposing across cancer types suggest potential druggability in up to 16% of tumors. The percentage of potential drug-associated tumors can increase to 48% if we consider preclinical evidence. Further, our analyses showed co-occurring potentially druggable multi-omics alterations in 32% of tumors, indicating a role for individualized combinational therapy, with evidence supporting mTOR/PI3K/ESR1 co-inhibition and BRAF/AKT co-inhibition in 1.6 and 0.8% of tumors, respectively. We experimentally validated a subset of putative druggable mutations in BRAF identified by a protein structure-based computational tool. Finally, analysis of a large-scale drug screening dataset lent further evidence supporting repurposing of drugs across cancer types and the use of expression outliers for inferring druggability. CONCLUSIONS:Our results suggest that an integrated analysis platform can nominate multi-omics alterations as biomarkers of druggability and aid ongoing efforts to bring precision oncology to patients.

SUBMITTER: Sengupta S 

PROVIDER: S-EPMC6064051 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Although large-scale, next-generation sequencing (NGS) studies of cancers hold promise for enabling precision oncology, challenges remain in integrating NGS with clinically validated biomarkers.<h4>Methods</h4>To overcome such challenges, we utilized the Database of Evidence for Precision Oncology (DEPO) to link druggability to genomic, transcriptomic, and proteomic biomarkers. Using a pan-cancer cohort of 6570 tumors, we identified tumors with potentially druggable biomarkers  ...[more]

Similar Datasets

| S-EPMC4297258 | biostudies-literature
| S-EPMC8183685 | biostudies-literature
| S-EPMC4406750 | biostudies-literature
| S-EPMC10410148 | biostudies-literature
| S-EPMC8452849 | biostudies-literature
| S-EPMC2797084 | biostudies-literature
2015-02-20 | E-GEOD-61383 | biostudies-arrayexpress
2015-02-20 | GSE61383 | GEO
| S-EPMC9374442 | biostudies-literature
| S-EPMC6050338 | biostudies-literature